Neratinib Clinical Trials
10 recruitingDrug
Phase 29Phase 11Phase 31
Showing 1–10 of 10 trials
Recruiting
Phase 3
Personalized Medicine for Advanced Biliary Cancer Patients
Biliary Tract Neoplasms
UNICANCER800 enrolled69 locationsNCT05615818
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Neurofibromatosis type 2MeningiomaEpendymoma+2 more
Scott R. Plotkin, MD, PhD109 enrolled6 locationsNCT04374305
Recruiting
Phase 1Phase 2
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Solid Tumor, Adult
Virginia Commonwealth University83 enrolled1 locationNCT03919292
Recruiting
Phase 2
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Breast CancerER Positive Breast CancerHER2-positive Breast Cancer+1 more
Ruth O'Regan30 enrolled4 locationsNCT04886531
Recruiting
Phase 2
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Gastric CancerGastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute36 enrolled1 locationNCT06109467
Recruiting
Phase 2
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
Advanced Breast Cancer
Dartmouth-Hitchcock Medical Center135 enrolled1 locationNCT05933395
Recruiting
Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Glioblastoma
Patrick Wen, MD460 enrolled12 locationsNCT02977780
Recruiting
Phase 2
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Anatomic Stage I Breast CancerAnatomic Stage II Breast CancerAnatomic Stage III Breast Cancer+1 more
Vanderbilt-Ingram Cancer Center30 enrolled5 locationsNCT05919108
Recruiting
Phase 2
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
Breast CancerHER2-positive Breast Cancer
University Health Network, Toronto15 enrolled1 locationNCT05388149